FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Italy Fines Apple €98.6 Million Over App Store Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
CHICAGO, Sept. 14, 2017 -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer.
As part of the research collaboration spanning multiple cancer subtypes, Tempus will provide molecular sequencing and analysis for patients enrolled in a precision oncology clinical study at Taussig Cancer Institute. This study is enrolling patients with advanced (metastatic or incurable) cancer who are running out of standard treatment options. The goal is to identify targeted therapies and/or clinical trials that a patient may be a good candidate for and to uncover patterns of clinical significance leading to more effective, personalized treatments.
“We are committed to supporting our clinicians and scientists in using complex information and advanced technology to care for our patients. Incorporating advanced genomic data may enhance our ability to analyze vast amounts of clinical and molecular data, as we seek to improve the treatment options for our patients,” said Dr. Brian J. Bolwell, chairman of Cleveland Clinic Taussig Cancer Institute, which is both an NCI-designated comprehensive cancer center and a top-ranked national provider of advanced cancer care to thousands of patients diagnosed with cancer every year.
“We are pleased to collaborate with Cleveland Clinic, a world-renowned hospital that has built its reputation by providing high quality care to its patients, and we’re thrilled to be supporting its efforts to further incorporate genomic data into their clinical and research practice,” said Eric Lefkofsky, Founder and CEO of Tempus.
About Tempus:
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.
Clo Ewing
Director of Communications at Tempus
[email protected]
